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TODA Y WE HAVE HEARD the prelimi-
nary assessment of a new immunosup-
pressive drug that has exceptional potential 
interest. Those who discovered FK-506 in 
Japan and all of the major workers who have 
examined its properties shared their informa-
tion in a remarkable display of generosity and 
frankness. 
The amicable tone for the meeting was set 
by the original Japanese workers from Fuji-
sawa Co, Ltd, Osaka, Japan, who described 
how knowledge of cyclosporine's (CyA) 
action guided their activities. They were look-
ing for a fungus or bacteria that could inhibit 
interleukin 2 synthesis. Having found Strep-
tomyces tsukubaensis in the soil not far from 
Tokyo, the steps of purification, structure 
delineation, and testing of the FK derivative 
proceeded rapidly. 
Much of clinical relevance is known about 
FK-506. It is more potent than CyA on a 
weight-for-weight basis in in vitro models and 
when tested in rat and dog transplant models. 
Under all these test conditions, it is synergistic 
with CyA. Presumably the same applies with 
other agents, which opens the immediate pos-
sibility that FK-506 could be an effective 
ingredient of polypharmaceutical therapy in 
which low doses of the constituent drugs will 
minimize toxicity. Considerable work has 
been done both on rats and dogs about the 
dose-effect relationships of FK-506 alone or 
given with CyA. 
The missing or incomplete information is 
about toxicity. There is little mortality or 
morbidity in rats, but dogs vomit and can 
develop lethal emaciation while receiving FK-
506. Widespread vasculitis has been seen in 
many canine organs including the kidneys, 
liver, heart, and pancreas, but not in the 
organs of rats and baboons. The consensus 
was that these were relatively species-specific 
findings in the dog. 
The pharmacokinetics of FK-506 are not 
known. The significance of toxic manifesta-
tions in dogs and even the lack of these 
manifestations in other species have not been 
definable without effective methods to assay 
the blood and tissue concentration of FK-506. 
Perfection of a highly sensitive enzyme immu-
noassay was announced at this meeting by 
scientists of Fujisawa. This means that the 
missing information can be filled in quickly 
during the next few months. Studies of subhu-
man primates will be particularly important 
because, if promising, these could premonitor 
phase I clinical trials. 
From the Department of Surgery, University Health 
Center of Pittsburgh, University of Pittsburgh. 
Address reprint requests to T.E. Starzl, MD, PhD, 
3601 Fifth Ave, Falk Clinic. Pittsburgh. PA 15213. 
© 1987 by Grone & Stratton,lnc. 
0041-1345/87/1905-6022$03.00/0 
Transplantation Proceedings. Vol XIX, No 5, Suppl 6 (October), 1987: p 103 103 
